The Next Generation of Newborn Screening
New review explores how next-generation sequencing could enhance early disease detection in newborns
Objective: To review the role of next-generation sequencing (NGS) in enhancing traditional newborn screening methods.
Key Findings: NGS can detect disease-causing genetic variants directly, allowing for earlier identification of inherited conditions. Pilot programs show that genomic screening can identify actionable genetic diseases missed by standard screening. Most current programs utilize targeted gene panels, whole-exome sequencing, or whole-genome sequencing on dried blood spots. Interpretation of genetic variants of uncertain significance poses a diagnostic challenge. Rapid sequencing pipelines can now deliver results in a median of 7 days for critically ill infants. Interpretation: Genomic newborn screening is evolving from experimental stages to structured implementation, enhancing the detection of serious genetic diseases.
Limitations: Bioinformatics infrastructure and variant interpretation capacity are critical requirements for laboratory adoption. Turnaround times for genomic screening have historically been longer than traditional methods. Conclusion: The integration of biochemical and genomic assays is expected to improve early detection of serious genetic diseases.
